Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers ( CORTAHF )

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Dec 19, 2022

Keywords

ClinConnect Summary

The CORTAHF clinical trial is investigating whether a short course of prednisone, a type of steroid, can help reduce inflammation in patients with acute heart failure (AHF) who come to the emergency department. Inflammation is a common issue in AHF and may worsen the condition. The study aims to see if giving prednisone for 7 days can make a difference in how patients respond and recover.

To participate in this trial, individuals should be between 18 and 85 years old, have recently visited the emergency department for breathing difficulties, and have specific blood markers indicating heart strain and inflammation. Participants will need to provide consent and agree to follow-up visits at the hospital after one week and again after 30 days. The trial is currently recruiting patients, and while it offers an opportunity to contribute to important research, it also has specific criteria to ensure safety and suitability for the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 to 85 years of age
• • 2. Unplanned ED visit within the 12 hours prior to Screening with acute or worsening dyspnea and/or orthopnea, and Pulmonary congestion on chest X-ray or lung ultrasound.
• • 3. All measures from presentation to randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm.
• • 4. Written informed consent to participate in the study.
• • 5. Affiliation to a french social security system (beneficiary or legal)
• • 6. Biomarker levels indicative of congestion and inflammation: At Screening, NT-proBNP \> 1,500 pg/mL or BNP\>375 pg/mL and CRP \> 40 mg/L
• • 7. Patient agrees for follow-up visit at the hospital at day 7 in case of earlier discharge and Day 30.
• Exclusion Criteria:
• • 1. Anticipated life expectancy less than 6 months
• • 2. Mechanical ventilation (not including CPAP/BIPAP) prior to Screening.
• • 3. Significant pulmonary disease contributing substantially to the patients' dyspnea such as FEV1\< 1 liter or need for chronic systemic or non- systemic steroid therapy, or any kind of primary right heart failure such as primary pulmonary hypertension or recurrent pulmonary embolism.
• • 4. Myocardial infarction, unstable angina or cardiac surgery within 3 months, or cardiac resynchronization therapy (CRT) device implantation within 3 months, or percutaneous transluminal coronary intervention (PTCI), within 1 month prior to inclusion.
• • 5. Index Event (admission for AHF) triggered primarily by a correctable etiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response \>130 beats per minute, or bradycardia with sustained ventricular arrhythmia \<45 beats per minute), infection, severe anemia, acute coronary syndrome, pulmonary embolism, exacerbation of COPD, planned admission for device implantation or severe non-adherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not an exclusion.
• • 6. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy.
• • 7. History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device.
• • 8. Sustained ventricular arrhythmia with syncopal episodes within the 3 months prior to screening that is untreated.
• • 9. Presence at screening of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation, or the presence of any hemodynamically significant obstructive lesion of the left ventricular outflow tract.
• • 10. Primary liver disease considered to be life threatening (defined by a prothrombin time \< 30%)
• • 11. eGFR \< 30 mL/min/1.73m2 or eGFR \> 80 mL/min/1.73m2 (as estimated by the simplified MDRD formula) at inclusion or history of dialysis.
• • 12. Systemic steroid therapy, within 30 days from inclusion.
• • 13. Inability to consent, or patient under guardianship measure
• • 14. Participation in another intervention trial in the past 30 days
• • 15. Anticipated non-adherence to study protocol or follow-up.
• • 16. Pregnant or nursing (lactating) women.
• • 17. Known hypersensitivity to steroids or constituents of prednisone tablets (excipients)
• • 18. Psychotic states not yet controlled by treatment
• • 19. Concomitant administration of live vaccines and up to 3 months before end of corticotherapy administration
• • 20. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom
• • 21. Persons subject to psychiatric care without their consent